Korro Bio (NASDAQ:KRRO) Posts Earnings Results, Beats Expectations By $0.07 EPS

Korro Bio (NASDAQ:KRRO) released its quarterly earnings data on Tuesday. The company reported ($2.26) EPS for the quarter, topping analysts’ consensus estimates of ($2.33) by $0.07, Zacks reports. The firm had revenue of $2.27 million for the quarter.

Korro Bio Trading Down 3.6 %

Shares of NASDAQ KRRO opened at $24.17 on Wednesday. Korro Bio has a 12-month low of $18.50 and a 12-month high of $98.00. The stock has a fifty day moving average price of $30.70 and a 200 day moving average price of $41.82.

Analyst Ratings Changes

A number of research firms have recently commented on KRRO. HC Wainwright restated a “buy” rating and set a $115.00 price objective on shares of Korro Bio in a report on Friday, November 22nd. Oppenheimer began coverage on Korro Bio in a report on Friday, January 10th. They set an “outperform” rating and a $155.00 price objective for the company. Six equities research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, Korro Bio currently has an average rating of “Buy” and an average target price of $144.00.

About Korro Bio

Korro Bio, Inc, a biopharmaceutical company, engages in the discovery, development, and commercialization of genetic medicines based on editing RNA for the treatment of rare and highly prevalent diseases primarily in the United States. Its lead product candidate is KRRO-110 which is in preclinical trials for the treatment of Alpha-1 Antitrypsin Deficiency (AATD).